E

$Eli Lilly(LLY.US) opened at $1,446.55 on Thursday, touched an all-time high of $1,460 intraday, but closed back down at…

$Eli Lilly(LLY.US) opened at $1,446.55 on Thursday, touched an all-time high of $1,460 intraday, but closed back down at $1,427.28—the low of the day—essentially flat for the session.

The catalyst was the NMPA's approval of the oral weight-loss drug orforglipron. $Eli Lilly(LLY.US) was the first to file for it, while Novo Nordisk's oral Wegovy is still awaiting approval in China. The classic 'buy the rumor, sell the news' pattern played out with a spike and fade on the day the good news landed.

Sentiment on the options side is shifting: Thursday saw ~49k contracts traded with a Put/Call ratio of 0.96, dipping below 1 for the first time in two weeks (previously ranging between 1.09 and 1.76 daily). However, the open interest P/C ratio remains at 1.39, indicating existing positions are still largely hedged with puts.

The stock has rallied ~14% over the past 20 days, with RSI at 74 (overbought territory), leaving about 6% upside to the 20-day MA at $1,347. New call volume suggests some FOMO buying, while persistent put O/I indicates holders are buying insurance. If $1,400 holds, continue holding; if it breaks, watch the 20-day MA first.

The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.